Immutep Limited (ASX: IMM) Reports Initial Safety Data for IMP761
Initial Safety Data Highlights
Immutep Limited (ASX: IMM) announces promising initial safety data from its ongoing Phase I trial of IMP761, the world’s first LAG-3 agonist. There have been no treatment-related adverse events reported to date across three of five single ascending dose cohorts involving healthy participants. The study aims to further evaluate safety and immunosuppressive efficacy, with additional data expected in the first half of CY2025.
Study Overview and Future Data
The trial, conducted by the Centre for Human Drug Research in Leiden, the Netherlands, involves up to 49 subjects. Its design includes a pharmacological activity assessment utilising a keyhole limpet haemocyanin challenge model. Immutep anticipates providing more extensive safety data and assessing pharmacokinetic and pharmacodynamic relationships in due course.
Executive Comments
Dr. Frédéric Triebel, Chief Scientific Officer at Immutep, expressed enthusiasm about the safety results, stating, “We are very encouraged by the safety data generated to date for IMP761… Derisking this promising asset in this proof-of-concept study is an important step for this exciting program in autoimmune diseases.” He noted the potential of IMP761 to address underlying causes of many autoimmune diseases and the company’s eagerness to gather further data from this study.
About IMP761
IMP761 is engineered to enhance the immune checkpoint function of LAG-3, potentially restoring balance in the immune system by silencing autoimmune memory T cells that contribute to various autoimmune conditions, including rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis. Initial preclinical studies have demonstrated its effectiveness in decreasing inflammatory cytokines and suppressing T cell-mediated immune responses.
About Immutep
Immutep is a clinical-stage biotechnology firm at the forefront of developing innovative LAG-3 immunotherapies for cancer and autoimmune diseases. With a commitment to advancing therapeutic options, Immutep seeks to maximise value for shareholders through its unique expertise in immune modulation.
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.